Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03025256|
Recruitment Status : Not yet recruiting
First Posted : January 19, 2017
Last Update Posted : October 25, 2017
This clinical research study consists of 2 phases: dose escalation (Phase 1) and dose expansion (Phase 2).
The goal of Phase 1 of this research study is to find the highest tolerable dose level of nivolumab that can be given both by intravenous (IV) infusion and intrathecal (IT) injection to patients with leptomeningeal disease (LMD). IV infusions are given by vein, while IT injections are given directly into the cerebrospinal fluid (CSF).
The goal of Phase 2 of this research study is to learn if the highest tolerable dose level combination found during Phase 1 can help to control the disease.
The safety of the drug combination will also be studied in both phases.
|Condition or disease||Intervention/treatment||Phase|
|Melanoma and Other Malignant Neoplasms of Skin Leptomeningeal Disease||Drug: Nivolumab||Phase 1|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||30 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||A Phase I/Ib Study of Concurrent Intravenous and Intrathecal Nivolumab for Patients With Leptomeningeal Disease (LMD)|
|Anticipated Study Start Date :||April 2018|
|Estimated Primary Completion Date :||April 2021|
|Estimated Study Completion Date :||April 2021|
Dose Escalation: Participants receive intrathecal (IT) Nivolumab every 14 days. Cycle 1 consists of IT Nivolumab only, but in subsequent cycles the IT Nivolumab dose is followed by an intervenous dose of Nivolumab.
Intrathecal dose administered by accessing the Ommaya.
Dose Expansion: Maximum tolerated dose from Dose Escalation.
Dose Escalation Intrathecal Nivolumab Starting Dose: 10 mg as an injection directly into CSF through Ommaya reservoir on Day 1 of each 14 day cycle for 2 cycles.
No intrasubject dose escalation, and subjects receive the same IT dose level during all subsequent cycles for up to 2 years, given tolerability.
Intravenous dose is 3 mg/kg for all participants.
Dose Expansion Intrathecal Nivolumab: Recommended dose from Intrathecal Nivolumab Dose Escalation Phase
- Recommended Dose of Combined IT and IV Nivolumab [ Time Frame: 28 days ]Recommended dose defined as the highest dose for which the posterior probability of toxicity is closest to 30%.
- Overall Survival (OS) with Combined IT and IV Nivolumab [ Time Frame: 12 months ]Kaplan-Meier method used to estimate the distribution of OS from the start of study treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03025256
|Contact: Isabella C. Glitza, MD, PHD||713-792-2921||CR_Study_Registration@mdanderson.org|
|Contact: Clinical Research Operations MD Anderson Cancer Center||713-792-7734||CR_Study_Registration@mdanderson.org|
|United States, Texas|
|University of Texas MD Anderson Cancer Center||Not yet recruiting|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Isabella C. Glitza, MD, PHD||M.D. Anderson Cancer Center|